Introduction
Binixen 15 mg (Binimetinib) is a potent, targeted oncology medication categorized as a MEK inhibitor. Manufactured by Everest Pharmaceuticals Ltd. and supplied globally by Onco Solution, this drug is a breakthrough in precision medicine. Binixen is specifically designed to treat cancers driven by the BRAF V600 mutation, including advanced melanoma and non-small cell lung cancer (NSCLC). It is typically used in combination with encorafenib to effectively block the pathways that allow cancer cells to grow and spread.+1
Indications
Binixen 15 mg (Binimetinib) is indicated for:
- Unresectable or Metastatic Melanoma: For adult patients with BRAF V600E or V600K mutations, as confirmed by an approved companion diagnostic test.
- Metastatic Non-Small Cell Lung Cancer (NSCLC): Treatment of adult patients with BRAF V600E mutations.
Pharmacology
Binimetinib, the active ingredient in Binixen, is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2. These kinases are critical components of the MAPK/ERK signaling pathway. In cancers with BRAF mutations, this pathway becomes hyperactive, causing unregulated cell proliferation. By inhibiting MEK1/2, Binixen prevents the activation of downstream effector proteins, leading to the inhibition of tumor growth and the induction of cancer cell apoptosis.+2
Dosage & Administration
Oral Administration for Adults:
- Standard Dose: 45 mg (three 15 mg tablets) taken orally twice daily, approximately 12 hours apart.
- Administration: Can be taken with or without food.
- Missed Dose: If a dose is missed, it can be taken up to 6 hours before the next scheduled dose. Do not take a double dose to make up for a missed one.
- Note: Always use in combination with encorafenib as directed by an oncology specialist.
Drug Interactions
- UGT1A1 Inducers: May decrease the plasma concentration of Binimetinib.
- CYP Enzymes: While primarily metabolized via glucuronidation, caution is advised when co-administered with strong inhibitors or inducers of metabolic pathways.
- Note: Always provide a full list of current medications to your healthcare provider before starting Binixen.
Contraindications
- Hypersensitivity: Known allergy to Binimetinib or any excipients in the tablet.
- Pregnancy: Potential for severe fetal harm.
- Severe Hepatic Impairment: Requires significant dose adjustment or avoidance.
Side Effects
Patients receiving Binixen 15mg may experience:
- Gastrointestinal: Nausea, diarrhea, vomiting, and abdominal pain.
- General: Fatigue, dizziness, and peripheral edema (swelling).
- Ocular: Visual disturbances, including blurred vision or retinal detachment (serous retinopathy).
- Musculoskeletal: Increased blood levels of creatine phosphokinase (CPK), muscle pain, or cramps.
- Vascular: High blood pressure (hypertension) or blood clots (VTE).
Pregnancy & Lactation
- Pregnancy Category: Potential fetal risk. Effective non-hormonal contraception must be used during treatment and for 30 days after the final dose.+1
- Lactation: Breastfeeding is not recommended during treatment and for at least 3 days after the last dose.
Precautions & Warnings
- Cardiac Monitoring: Monitor Left Ventricular Ejection Fraction (LVEF) before and during treatment.
- Ophthalmologic Exams: Regular eye exams are required to monitor for serous retinopathy or retinal vein occlusion.
- Liver Function: Periodic liver function tests (LFTs) are necessary to monitor for hepatotoxicity.
- Muscle Health: Monitor CPK levels, especially if the patient experiences unexplained muscle pain or weakness.
Use in Special Populations
- Hepatic Impairment: Patients with moderate to severe hepatic impairment require a reduced dose (typically 30 mg twice daily).
- Pediatric Use: Safety and efficacy have not been established in children.
Overdose Effects
Symptoms of overdose may include exaggerated side effects such as severe gastrointestinal distress or muscle toxicity. Management involves immediate supportive care and monitoring by medical professionals.
Storage
- Condition: Store at room temperature (15–30°C).
- Protection: Keep in the original container to protect from moisture and light. Keep out of reach of children.
Supplier Information
Onco Solution is a premier global oncology medicine supplier, dedicated to ensuring that life-saving treatments like Binixen 15mg reach patients worldwide. For global supply inquiries, visit www.oncosolution.com.
Manufacturer Information
Binixen 15mg is manufactured by Everest Pharmaceuticals Ltd., a leading name in the production of specialized oncology and high-tech generic medicines in Bangladesh. For more details, visit www.everestpharmabd.com.
